The PennZone

  • Home
  • Education
  • Non-profit
  • Technology
  • Construction
  • Health
  • Entertainment
  • Marketing
  • Business

TCB Capital Advisors Congratulates Altoida & Gregor Diagnostics on 2024 Merit Awards Recognition
The PennZone/10286921

Trending...
  • Philadelphia's Own Reverend Jamie Knight Returns with "Award-Winning Love
  • Kolbus Introduces the Next Step in Casemaking Efficiency
  • Heavy Duty Journal Surpasses 1000 Technical Articles for Diesel Technicians and Fleet Managers
THE WOODLANDS, Texas - PennZone -- TCB Capital Advisors proudly announces two of its partners, Altoida Inc. and Gregor Diagnostics Inc., have been recognized by the 2024 Merit Awards for Healthcare. These awards celebrate companies demonstrating groundbreaking advancements in medical technology, healthcare innovation, and patient care.

Altoida received the Gold Award for "Best Use of Artificial Intelligence," a testament to its leadership in digital health and AI applications that enhance the early detection of neurodegenerative diseases, including Alzheimer's. Altoida's pioneering NeuroMarker Platform utilizes a tablet-based application powered by augmented reality (AR) and artificial intelligence/machine learning (AI/ML) designed to deliver rapid and objective multi-modal assessment of cognitive health and function. The platform aim's to equip frontline clinicians with clinical insights to enable earlier detection, personalized care and to lead to improved patient outcomes.

Gregor Diagnostics earned the Bronze Award in the "Innovations" category, underscoring the company's achievements in developing revolutionary diagnostic solutions. Gregor Diagnostics is dedicated to pioneering advancements in prostate cancer detection, aiming to deliver earlier and more precise diagnostics for better patient outcomes.

"It's truly an honor to see Altoida and Gregor Diagnostics acknowledged for their groundbreaking work," Sam Libby, President and Managing Director at TCB Capital Advisors, expressed. "The Merit Awards spotlight innovators who are reshaping the future of healthcare, and we at TCB are so proud to support such visionary leaders who are driving remarkable advancements in patient care and medical science."

More on The PennZone
  • ET&T Adds Senior Technical Voice Engineer to Strengthen Local Team
  • Stepping Off the Grid: Savista Retreat Announces New Experiential Packages in Jaipur for Travellers
  • Where Is Your Faith The Movie and Sountrack
  • Bynn Intelligence Ranks #1 in NIST Child Online Safety Evaluation for Ages 13–16
  • Rev-O-Box™ Launches Reversible Shipping Box That Instantly Becomes a Premium Gift Box

The 2024 Merit Awards for Healthcare highlights outstanding achievements across various healthcare sectors, selecting winners based on their significant impact on improving healthcare delivery and innovation.

For more information please visit Altoida and Gregor Diagnostics. To learn more about TCB Capital Advisors, visit TCB Capital Advisors.

About Altoida
Altoida is the leader in developing digital biomarkers for neurological conditions, including Alzheimer's disease. Its innovative Altoida Digital NeuroMarker Platform leverages artificial intelligence and augmented reality (AR) to deliver objective and precise assessments of cognitive health. The platform uses a tablet-based app that offers a quick, self-administered series of motor, speech, and AR tasks, simulating daily activities to evaluate brain health. These tasks measure key cognitive metrics, including micro-movements, processing speed, reaction time, and spatial navigation. Altoida is a privately held, venture-backed diagnostics company with a proprietary platform built on over 20 years of scientific research. Its evidence-based technology has been featured in numerous global pharmaceutical studies and published in prestigious peer-reviewed journals, including Nature Digital Medicine.

About Gregor Diagnostics
Gregor Diagnostics Inc. is a molecular diagnostics company developing groundbreaking diagnostics for prostate cancer. Gregor Diagnostics' patient-friendly test is sensitive enough to detect prostate cancer at the earliest stages of the disease and differentiate between indolent and aggressive cancer upon detection. Gregor Diagnostics is making early detection and less invasive identification and management of prostate cancer a reality while decreasing the overdiagnosis and overtreatment of indolent prostate cancer.

More on The PennZone
  • Las Vegas Estate Firm Ghandi Deeter Blackham Offers Insight on Tony Hsieh's Contested $500 Million Will
  • CCHR: Congressional Hearing Revives Lessons from MKULTRA Era – Why Past Psychiatric Human Rights Abuses Demand Vigilance Today
  • Pacto Medical Wins Red Dot Design Concept Award 2026 for Slimshot® Compact Prefilled Syringe
  • Heritage at Manalapan Introduces Luxury Single-Family Homes with Exceptional Value in One of Monmouth County's Most Desirable Locations
  • Achugogo: Tale of the Spring Chaser Wins Inaugural TCCF Prize at Mifa Pitches, the Industry Market of the Annecy International Animation Film Festival

About TCB Capital Advisors

TCB Capital Advisors is a boutique investment bank and advisory firm focused on the healthcare and life sciences sectors. The firm specializes in advising clients with their buying, selling, investment, and growth strategies, leveraging decades of combined Wall Street and industry experience. TCB Capital Advisors offers a tailored approach, focusing on transaction advisory, corporate development, revenue growth, and post-transaction integration, working with clients across venture, growth, and middle-market verticals. Founded in 2023 by former members of the healthcare team at Piper Sandler, TCB Capital Advisors is headquartered in Houston, TX with offices/team members based in New York, North Carolina, and Tennessee. Securities are offered through Finalis Securities, LLC (member FINRA/SIPC). TCB Capital Advisors is not a registered broker-dealer, and Finalis Securities, LLC and TCB Capital Advisors are separated, unaffiliated entities. For more information, please visit www.tcbcapitaladvisors.com.

Contact
Melinda Jackson Public Relations
***@melindajacksonpr.com


Source: TCB Capital Advisors
Filed Under: Business, Health

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Dave Freer's "Storm-Dragon" Wins First-Ever Prometheus Special Award For Young Adult Fiction
  • T. Jones Group Celebrates Two Wins and Multiple Project Nominations at the 2026 HAVAN Awards
  • Studica Robotics Supports Robotics Training Camp for WorldSkills Shanghai 2026
  • Lineus Medical Renews Agreement with Vizient, Delivering Enhanced Value for Vizient Members
  • Pittsburgh Divorce Attorney Candice L. Komar Elected Chair of PBA Family Law Section
  • Grace Montessori School Receives $30,000 from Payne Foundation and $12,000 from Trexler Trust to Sup
  • Qscription Technologies Appoints Radiology Industry Veteran Elliot Silverman to Advisory Board
  • Search Is Broken. Curated Discovery Is the Future
  • 20 Ways to Save Money Running a Van
  • How Fortress Law Group Turned a DUI Arrest in Ohio Into a Full Acquittal at Trial
  • Breaking the Silence: Tour Sparks National Conversation on Men's Mental Health and Domestic Abuse
  • Mr. Hospital Bed Helps Home Care Buyers Find the Right Hospital Bed
  • New School Announces Student Enrollment
  • Able Rooter Expands Services to Offer Premium Water Heater Installation Across St. Louis
  • Director Sean McNamara Reunites with Award-Winning Cinematographer Shawn Seifert for Upcoming Feature Home
  • J. Kenton Pierce Wins Prometheus Award for Best Novel
  • Ezra Wohlgelernter Named as a 2026 Philadelphia Power Broker by City & State PA
  • Class is in session: Black Beauty Block Party returns to Los Angeles for fourth annual festival
  • Heavy Duty Journal Surpasses 1000 Technical Articles for Diesel Technicians and Fleet Managers
  • Brett Furman Launches Ranks Grow

Popular on PennZone

  • ReviewsAlly Launches Evidence-Based Review Platform for VPNs, Business Software, and Online Services - 103
  • Top 5 Most Reliable Used Vans in the UK in 2026
  • Sylvester Anthony III Introduces His Artist Journey with Debut Single "Cherish"
  • Together We Thrive: Kingdom Life Health & Career Fair Unites Faith, Wellness and Opportunity
  • Compton to host first Juneteenth celebration with We Are Us Festival
  • Proper Sky Named to the 2026 MSP 501
  • Week 47 Final Freedom Vigil at Alligator Alcatraz: Truth Out
  • What Happens When Congress Says No? New Book Examines the Boland Amendments, Iran-Contra Affair & Jamaican Posse, as US Congress Debate Over Military
  • Christmas Miracle Chronicles - New movie coming up this holiday season !
  • Psychiatric Hospitals Fail to Warn Electroshock Patients of FDA-Cited Risks in Estimated $7 Billion Industry

Similar on PennZone

  • Missouri Hemp Businesses File Federal Lawsuit Challenging HB 2641
  • Boston Industrial Solutions Launches New Citrine® SA1-370 Silicone Glue for Permanent Adhesion
  • Northeast Airlines Launches New Asset Management Group
  • AI Visibility Labs LLC - Dallas Texas - July 16 2026
  • NextBoat's AI-Powered Marine Marketplace Gains Momentum as Record Growth Signals an Inflection Point for Investors (N Y S E American: NXB)
  • Bynn Intelligence Ranks #1 in NIST Child Online Safety Evaluation for Ages 13–16
  • CCHR: Congressional Hearing Revives Lessons from MKULTRA Era – Why Past Psychiatric Human Rights Abuses Demand Vigilance Today
  • Pacto Medical Wins Red Dot Design Concept Award 2026 for Slimshot® Compact Prefilled Syringe
  • Is the Market Missing One of the Most Undervalued Cybersecurity Companies on the Stock Market? Cycurion, Inc. (N A S D A Q: CYCU):
  • Billion-Dollar Scale Global Technology Powerhouse Being Built with Expanding Government Contracts: Circle8 Group (N A S D A Q: CIRC)
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us